Nerlynx
Total Payments
$14.3M
Transactions
13,399
Doctors
3,655
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2021 | $9,650 | 7 | 6 |
| 2019 | $7.5M | 6,769 | 2,418 |
| 2018 | $6.8M | 6,623 | 2,475 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $10.8M | 819 | 75.0% |
| Consulting Fee | $1.7M | 474 | 11.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.1M | 357 | 8.0% |
| Travel and Lodging | $389,549 | 1,723 | 2.7% |
| Food and Beverage | $276,697 | 9,793 | 1.9% |
| Space rental or facility fees (teaching hospital only) | $78,444 | 43 | 0.5% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $5,897 | 7 | 0.0% |
| Education | $1,895 | 183 | 0.0% |
Payments by Type
Research
$10.8M
819 transactions
General
$3.6M
12,580 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors | Puma Biotechnology, Inc. | $1.7M | 0 |
| An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal | Puma Biotechnology, Inc. | $1.6M | 0 |
| An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early | Puma Biotechnology, Inc. | $1.6M | 0 |
| . | Puma Biotechnology, Inc. | $1.4M | 0 |
| An Open?Label Study to Characterize the Incidence and Severity of Diarrhea | Puma Biotechnology, Inc. | $1.0M | 0 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine(NALA) | Puma Biotechnology, Inc. | $301,426 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib | Puma Biotechnology, Inc. | $298,949 | 1 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in Patients with HER2+ | Puma Biotechnology, Inc. | $286,452 | 0 |
| IMPACT Profiling in Patients with Advanced Cervix Cancer | Puma Biotechnology, Inc. | $275,250 | 0 |
| Evaluating Neratinib in orthotopic PDX models of breast cancer brain metastases | Puma Biotechnology, Inc. | $232,418 | 0 |
| A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab | Puma Biotechnology, Inc. | $163,486 | 1 |
| An Open-label, Phase 1, Single-Dose Study to Determine the Mass Balance Recovery | Puma Biotechnology, Inc. | $160,421 | 0 |
| Identification of Therapeutic Molecular Targets that Enhance Anti-Tumor Activity | Puma Biotechnology, Inc. | $141,457 | 0 |
| Systematic Characterization of activating HER2 mutations using mutagenesis | Puma Biotechnology, Inc. | $95,953 | 0 |
| Preclinical evaluation of neratinib in tumor cell lines, and patient derived xenograft (PDX) models | Puma Biotechnology, Inc. | $80,013 | 0 |
| SRA Pre-clinical study Dr. Santin _In vitro and In vivo | Puma Biotechnology, Inc. | $69,455 | 0 |
| An Open-label, Randomized, 3-Period, Crossover, Drug-Drug Interaction Study to Evaluate the Effect | Puma Biotechnology, Inc. | $57,853 | 0 |
| A Study of Neratinib Plus Capecitabine versus Lapatinib Plus Capecitabine in Patients - NALA | Puma Biotechnology, Inc. | $52,510 | 0 |
| SRA - Combination of Neratinib with Other Targeted Therapy in HER2+ Endometrial and Ovarian Cancers | Puma Biotechnology, Inc. | $45,500 | 0 |
| A Phase 1, Open-Label, Single Dose Study to Assess the Absorption, Metabolism, and Excretion of Nera | Puma Biotechnology, Inc. | $32,709 | 0 |
Top Doctors Receiving Payments for Nerlynx
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Jackson, MS | $10.8M | 855 |
| , MD | Pediatric Hematology-Oncology | Los Angeles, CA | $469,200 | 35 |
| , MD | Medical Oncology | Somerville, MA | $222,088 | 26 |
| , MD | Medical Oncology | Mcallen, TX | $133,213 | 215 |
| , MD | Internal Medicine | Miami, FL | $115,849 | 137 |
| , MD | Medical Oncology | Winston Salem, NC | $111,349 | 163 |
| , M.D., M.P.H | Medical Oncology | South San Francisco, CA | $106,241 | 32 |
| , MD | Internal Medicine | N New Hyde Pk, NY | $106,127 | 120 |
| , M.D | Medical Oncology | Leawood, KS | $102,966 | 124 |
| , MD | Hematology & Oncology | Indianapolis, IN | $74,926 | 78 |
| , MD | Medical Oncology | Albany, NY | $73,957 | 73 |
| , MD | Hematology & Oncology | Topsham, ME | $56,518 | 56 |
| , MD | Hematology & Oncology | Jacksonville, FL | $55,552 | 51 |
| , MD | Specialist | Pittsburgh, PA | $55,374 | 71 |
| , M.D | Hematology & Oncology | Flossmoor, IL | $54,896 | 95 |
| , MD | Medical Oncology | Newnan, GA | $50,931 | 76 |
| , M.D | Hematology & Oncology | Beverly Hills, CA | $48,400 | 75 |
| , M.D | Medical Oncology | Gardner, MA | $45,897 | 76 |
| , M.D., F.A.C.P | Internal Medicine | Cucamonga, CA | $45,472 | 48 |
| , M.D | Hematology & Oncology | Sioux Falls, SD | $43,262 | 61 |
| , M.D | Medical Oncology | S Pasadena, CA | $41,831 | 37 |
| , MD | Medical Oncology | Plano, TX | $36,953 | 48 |
| , MD | Medical Oncology | San Antonio, TX | $36,903 | 34 |
| , M.D | Internal Medicine | Las Vegas, NV | $35,738 | 60 |
| , MD | Internal Medicine | Albemarle, NC | $35,245 | 44 |
Ad
Manufacturing Companies
- Puma Biotechnology, Inc. $14.3M
Product Information
- Type Drug
- Total Payments $14.3M
- Total Doctors 3,655
- Transactions 13,399
About Nerlynx
Nerlynx is a drug associated with $14.3M in payments to 3,655 healthcare providers, recorded across 13,399 transactions in the CMS Open Payments database. The primary manufacturer is Puma Biotechnology, Inc..
Payment data is available from 2018 to 2021. In 2021, $9,650 was paid across 7 transactions to 6 doctors.
The most common payment nature for Nerlynx is "Unspecified" ($10.8M, 75.0% of total).
Nerlynx is associated with 20 research studies, including "An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors" ($1.7M).